drugset / Trial / NCT07030894
Nefecon and Ambrisentan in IgA Nephropathy
NaSingle-groupOpen-labelTreatment
Summary
Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and delaying eGFR progression, and observing changes in serum Gd-IgA1 levels
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ambrisentan | Small molecule | 5 mg | Oral |
| Subject | Budesonide | Small molecule | 16 mg | Oral |